Explore This Research Award in CaptureIQ
Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.
Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- ADAMAS NANOTECHNOLOGIES INC
- Proposal award date
- 2021-09-10
- Contract end date
- 2022-08-31
- UEI
- XV1FPSTT7LF4
- Solicitation number
- PA20-260
- Topic code
- NIGMS
Research abstract
Summary
Reactive oxygen species (ROS) are key mediators in human health but when misregulated can contribute to the
progression of many diseases (e.g., cardiovascular disease, Parkinsonandapos;s disease, Alzheimerandapos;s disease, cancer,
Downandapos;s syndrome, cataract, several neurological disorders, etc.). While biological effects of ROS are thought to
be determined by their both spatial (subcellular localization) and temporal (duration of exposure) levels, detailed
understanding of site-specific ROS intracellular concentrations and their relationship to the disease pathogenesis
is currently missing. The main reason for this is the commercial unavailability of experimental tools to detect and
characterize ROS at specific cellular locations with sufficient sensitivity and spatial and temporal resolution.
Electron paramagnetic resonance (EPR) is considered to be the gold standard for unambiguous chemical
identification of ROS by spin-trapping methods. However, the technical barriers for implementation are high, and
efforts toward developing EPR-based imaging of ROS within a biological environment have proven difficult.
Methods based on changes in fluorescence emission upon reactions of a dye with ROS are more accessible
than EPR. While such optical methods can be readily combined with cellular imaging, the current
implementations are riddled with difficulties including lack of specificity in ROS detection, toxicity concerns,
artefactual ROS production by the probes themselves, signal variability due to high levels of background
fluorescence and, importantly, photobleaching. This phase I proposal advances the field of ROS detection by
developing a new family of nanodiamond (ND) based bright fluorescent ROS sensors that will combine the
specificity and information content of EPR spin trapping with the advanced imaging capabilities enabled by
optical probes without the problems of phototoxicity and photobleaching. Our pathway to commercialization
assembles a team with expertise in ND processing and commercialization, development of cutting-edge ROS
detection schemes in EPR and chemical synthesis, and expertise in free radical biology and oxidative stress.
Phase I is aimed at demonstrating a proof-of-principle prototype ROS sensor which consists of spin-reactive
molecules crafted on ND surface and correlating fluorescence and EPR data. The ROS sensor will then be
tested in vitro to detect superoxide radical produced by a xanthine oxidase system and then detection and
imaging ROS in RAW264.7 macrophages. Benchmarking of ND over conventional ROS optical probes will be
aimed to demonstrate advantages of ND ROS sensors in extending the observation period and reducing resultsandapos;
variability. Commercialization of these new ROS detection tools will enable longitudinal studies of site-specific
ROS production in cells and tissue to advance the understanding of the roles of ROS and oxidative stress in the
pathogenesis and progression of diseases not otherwise achievable. Moreover, the adaption ND-NV-based spin
probes to ex vivo clinical diagnostics has high a commercial potential.Narrative
This project demonstrates the feasibility of a new class of reactive oxygen species (ROS) spin sensors that
significantly improve the reliability and resolution of measurement. The probes are based on non-toxic
photostable fluorescent nanodiamond particles which enable optical detection and imaging of ROS in biological
specimens with the capability for cross-examination by electron paramagnetic resonance (EPR) spectroscopy
to significantly enhance the fidelity of ROS determination. These probes will contribute to understanding the
mechanisms controlling ROS production at the cellular level, which can more readily elucidate the role of these
reactive species in the pathogenesis and the progression of diseases such as cardiovascular diseases, diabetes,
Alzheimerandapos;s disease, and cancer among others.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
Research funding history
11 SBIR/STTR records share this UEI (2013–2024). Reported award amounts total $7,187,187. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, Department of Energy
Agency intelligence
Department of Health and Human Services
Back to SBIR/STTR Research Awards